APTOF · Aptose Biosciences Inc.
$1.69
+0.00 (+0.00%)
At close · Jul 3
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“our ability to continue as a going concern; - our need to raise substantial additional capital in the near future and our ability to raise such funds when needed and on acceptable terms; - if a financing is completed, it may not be a large enough financing to fully fund the company's operations”View the 10-Q filed May 13, 2026
Market Cap
$4.31M
Shares
2.55M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| all of the directors of the Company | directors | Resigned | 2026-07-01 |
| Carol Ashe | member of the Board | Resigned | 2025-06-18 |
| Dr. Bernd R. Seizinger, M.D., Ph.D. | Board of Directors | Appointed | 2022-09-16 |
| Fletcher Payne | Senior Vice President and Chief Financial Officer | Appointed | 2022-06-28 |
| Jotin Marango | Senior Vice President, Chief Financial Officer and Chief Business Officer | Resigned | 2022-04-11 |
| Philippe Ledru | Chief Commercial Officer | Appointed | 2022-04-11 |
| Philippe Ledru | Chief Commercial Officer | Appointed | 2022-04-11 |
| Jotin Marango | Chief Accounting Officer | Appointed | 2021-05-04 |
| Jotin Marango | Chief Financial Officer | Appointed | 2021-05-04 |
| Gregory Chow | Executive Vice President and Chief Financial Officer | Resigned | 2021-03-29 |